Evidence map›Paper›PMID 36499608›Full record

ArticleInternational journal of molecular sciences2022

Nucleoside Analogs and Perylene Derivatives Modulate Phase Separation of SARS-CoV-2 N Protein and Genomic RNA In Vitro.

Julia Svetlova, Ekaterina Knizhnik, Valentin Manuvera, Vyacheslav Severov, Dmitriy Shirokov, Ekaterina Grafskaia, Pavel Bobrovsky, Elena Matyugina, Anastasia Khandazhinskaya, Liubov Kozlovskaya and 7 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Julia SvetlovaFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
Ekaterina KnizhnikDepartment of Molecular and Translational Medicine, Moscow Institute of Physics and Technology, 141701 Dolgoprudny, Russia.ORCID 0000-0001-9437-3622
Valentin ManuveraFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.ORCID 0000-0002-2471-0563
Vyacheslav SeverovFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.ORCID 0000-0002-5153-3515
Dmitriy ShirokovFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
Ekaterina GrafskaiaFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.ORCID 0000-0001-8957-6142
Pavel BobrovskyFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.ORCID 0000-0001-5735-0042
Elena MatyuginaEngelhardt Institute of Molecular Biology, Russian Academy of Science, 119991 Moscow, Russia.ORCID 0000-0002-4981-7316
Anastasia KhandazhinskayaEngelhardt Institute of Molecular Biology, Russian Academy of Science, 119991 Moscow, Russia.ORCID 0000-0003-1452-0253
Liubov KozlovskayaChumakov Federal Scientific Center for Research, Development of Immune-and-Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Nataliya MiropolskayaInstitute of Molecular Genetics, National Research Centre 'Kurchatov Institute', 123182 Moscow, Russia.
Andrey AralovShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, 117997 Moscow, Russia.ORCID 0000-0003-3268-2352
Yuri KhodarovichShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, 117997 Moscow, Russia.ORCID 0000-0002-0162-4857
Vladimir TsvetkovFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.ORCID 0000-0003-0494-3332
Sergey KochetkovEngelhardt Institute of Molecular Biology, Russian Academy of Science, 119991 Moscow, Russia.
Vassili LazarevFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
Anna VarizhukFederal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 119435 Moscow, Russia.
Federal Medical-Biological Agency · RUEngelhardt Institute of Molecular Biology · RUMoscow Institute of Physics and Technology · RUInstitute of Bioorganic Chemistry · RUKurchatov Institute · RUMoscow State Academy of Veterinary Medicine and Biotechnology named after Skryabin · RUPeoples' Friendship University of Russia · RURussian Academy of Sciences · RUSechenov University · RU

Funding

Council for Grants of the President of the Russian Federation MD-5000.2022.3Ministry of Science and Higher Education of the Russian Federation "Analogues of nucleic acid components as potential inhibitors of coronaviruses"Russian Foundation for Basic Research 20-04-60571Russian Science Foundation 19-74-10048Russian Science Foundation 22-25-00161
6 · The paper itself

Abstract

The life cycle of severe acute respiratory syndrome coronavirus 2 includes several steps that are supposedly mediated by liquid-liquid phase separation (LLPS) of the viral nucleocapsid protein (N) and genomic RNA. To facilitate the rational design of LLPS-targeting therapeutics, we modeled N-RNA biomolecular condensates in vitro and analyzed their sensitivity to several small-molecule antivirals. The model condensates were obtained and visualized under physiological conditions using an optimized RNA sequence enriched with N-binding motifs. The antivirals were selected based on their presumed ability to compete with RNA for specific N sites or interfere with non-specific pi-pi/cation-pi interactions. The set of antivirals included fleximers, 5'-norcarbocyclic nucleoside analogs, and perylene-harboring nucleoside analogs as well as non-nucleoside amphiphilic and hydrophobic perylene derivatives. Most of these antivirals enhanced the formation of N-RNA condensates. Hydrophobic perylene derivatives and 5'-norcarbocyclic derivatives caused up to 50-fold and 15-fold enhancement, respectively. Molecular modeling data argue that hydrophobic compounds do not hamper specific N-RNA interactions and may promote non-specific ones. These findings shed light on the determinants of potent small-molecule modulators of viral LLPS.

Indexed as

COVID-19PeryleneAntiviral AgentsHumansNucleosidesRNASARS-CoV-2Antiviral AgentsNucleosidesPeryleneRNAnucleocapsid proteinphase separationRNASARS-CoV-2small-molecule antivirals

Identifiers

PMID36499608
PMCPMC9738865
OpenAlexW4311629913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.